A biotech breakout has sent shockwaves through the market with a 500% surge, a household brand is jumping after a major tech investment, and a crypto-first strategy just catapulted a betting firm’s valuation. Here's what traders are watching today.
Hot Sectors (Sponsored)
As we dive into Q2 2025, the stock market is buzzing with opportunities, and I’ve got the insider scoop just for you.
I’ve handpicked the Top Seven Stocks for this quarter, offering you a clear roadmap for growth as the year progresses.
Here’s what makes this guide indispensable:
High-Growth Sectors: Key industries poised to boom this summer.
In-Depth Analysis: Simplified insights to make wise investment decisions.
Expert Picks: Data-driven, not just guesses, for reliable potential.
Profit-Boosting Opportunities: Position your portfolio for a strong finish in 2025.
This isn’t merely a list; it’s your chance to seize the market’s hottest opportunities before they pass you by.
Futures 📈
Want to make sure you never miss a premarket alert?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.
Email’s great. Texts are faster.
You’ll be first in line when the market starts moving.
What to Watch
Earnings:
AZZ Inc. [AZZ]: Aftermarket
Methode Electronics Inc. [MEI]: Aftermarket
Bassett Furniture Industries Inc. [BSET]: Aftermarket
Economic Reports:
Wholesale Inventories: 10:00 am
Minutes of Fed's May FOMC Meeting: 2:00 pm
Steady Performers (Sponsored)
Every strong portfolio starts with a reliable core — and this new report may help investors build exactly that.
“7 Stocks to Buy and Hold Forever” highlights a group of companies with a track record of steady performance, strong fundamentals, and long-term growth potential.
These stocks were chosen for a reason — and could help lay the groundwork for a strategy built to outlast short-term swings.
Retail
Ray-Ban Maker Jumps on Reported $3.5B Meta Investment
EssilorLuxottica (ESLOF) shares surged nearly 6% on Wednesday following reports that Meta (META) has taken a minority stake in the iconic eyewear maker.
According to Bloomberg, the investment is worth approximately €3 billion ($3.5 billion) at current market value, and Meta may be considering an expansion of its ownership stake to as much as 5%. While neither company has confirmed the deal, markets quickly reacted to the possibility of a deepened strategic partnership.
The investment underscores Meta’s growing commitment to artificial intelligence–driven wearable technology, a major focus for CEO Mark Zuckerberg as the company pushes further into hardware.
Meta and EssilorLuxottica first partnered in 2019 to launch a line of Ray-Ban smart glasses. Though the initial launch in 2021 generated limited excitement, the second-generation version released in 2023 gained significantly more traction thanks to improved functionality and the addition of Meta’s AI voice assistant.
The current models enable users to identify landmarks, suggest recipes by scanning ingredients, and record and send voice messages directly through WhatsApp and Messenger, all via visual and voice inputs when connected to a smartphone.
CEO Francesco Milleri revealed earlier this year that more than 2 million pairs of the Ray-Ban Meta smart glasses have been sold since late 2023, and production is being ramped up to target 10 million units annually by 2026.
Looking ahead, the companies also plan to release versions under the Oakley and Prada brands, positioning the product line for broader demographic reach and continued growth in the AI wearables market.
Biotech
ProKidney Rebounds Over 500% on Promising Phase 2 Results
ProKidney Corp. (PROK) saw its stock skyrocket over 500% on Tuesday and is up another 29% in premarket trading after releasing positive topline results from its Phase 2 REGEN-007 trial and receiving a price target upgrade from Citi.
The study evaluated the company’s lead candidate, rilparencel, in patients with diabetes and chronic kidney disease, and the early data significantly outperformed expectations.
The highlight came from Group 1 of the trial, where both kidneys were injected with the therapy. Patients in this group demonstrated a statistically significant improvement in the annual rate of kidney function decline, as measured by the eGFR slope.
According to Citi, this outcome exceeds both internal projections and management's expectations, potentially positioning ProKidney for accelerated approval in Phase 3 pending FDA review.
Citi raised its price target from $6.00 to $9.00 and increased the estimated probability of success for rilparencel by 10 percentage points to 60%. Despite its historical losses, ProKidney’s financials remain stable, with liquidity strength highlighted by a current ratio of 11x and more cash than debt.
ProKidney plans to present full data at the American Society of Nephrology’s Kidney Week later this year.
Though BofA Securities downgraded the stock to Underperform, citing a more conservative long-term sales outlook, the overwhelming market response reflects renewed investor confidence in the company’s late-stage development path and its potential to address a multi-billion-dollar unmet need in chronic kidney disease.
Gold vs. Paper (Sponsored)
Big banks are making moves — legally treating gold as a cash-equivalent asset under new regulations.
Meanwhile, millions remain heavily invested in volatile paper assets with rising exposure to risk.
One economist recently called gold “the only money banks trust.”
There’s still time to adjust, using an IRS-approved strategy that avoids taxes and penalties — and a free guide breaks it all down.
This Wealth Protection Guide outlines how to reposition before the opportunity tightens.
[Click here to access the guide]
P.S. Every day the smart money moves further ahead. The longer the delay, the more ground they gain.
Crypto
SharpLink Rallies Again as Ether Hoard Passes $500M
SharpLink Gaming (SBET) extended its rally into Wednesday’s premarket after announcing a new series of Ethereum purchases, which pushed its total crypto holdings to over $533 million. Shares soared 28.6% on Tuesday and were up another 12% in early trading as of Wednesday morning.
Between June 28 and July 4, SharpLink acquired 7,689 Ether (ETH) for more than $19 million at an average price of $2,501.
The sports betting company now holds 205,634 ETH and has committed 100% of it to staking and restaking operations, generating 322 ETH (worth roughly $849,000) in rewards since June 2.
The aggressive crypto strategy is being funded through equity sales. SharpLink raised $64 million in net proceeds from the sale of over 5.4 million shares last week, following an earlier $30 million Ether purchase on June 25. The company has also filed to sell up to $1 billion in common shares, aiming to further expand its Ether holdings.
SharpLink’s chairman, Ethereum co-founder Joseph Lubin, has championed the company’s shift toward an “ETH-centric treasury,” highlighting its commitment to transparency and a new internal metric called “ETH Concentration” to reflect exposure.
While many firms have added Bitcoin to their treasuries, SharpLink’s bold Ether-first approach is drawing attention.
With momentum continuing, investors are watching to see whether the company’s crypto-heavy strategy turns into a long-term edge or a risky bet amid market volatility.
Movers and Shakers
The AES Corporation [AES] – Last Close: $11.07
AES is a global energy company operating across utilities and power generation, with a growing focus on renewable and clean energy solutions. It manages assets in 14 countries and plays a key role in advancing energy transition strategies through wind, solar, and battery storage projects.
Shares are up over 13% in premarket trading after the company confirmed it will divest from some underperforming international operations and reinvest into faster-growing clean energy projects. The move comes amid rising demand for grid stability and carbon-free power solutions, particularly in North America.
My Take: AES is repositioning itself as a serious contender in the green energy shift. The strategic asset reshuffling may unlock long-term value, but execution risks remain. This is a solid name for climate-conscious investors with a long horizon.
Beam Therapeutics Inc. [BEAM] – Last Close: $20.30
Beam Therapeutics is a clinical-stage biotechnology company pioneering base editing, a next-generation gene editing approach with applications in rare diseases and oncology. The company’s CRISPR-based platform enables precise, single-base DNA edits without disrupting the DNA strand.
The stock is up nearly 6% in premarket following its updated pipeline presentation, which showcased promising data on its sickle cell and leukemia programs. Analysts are increasingly optimistic about Beam’s differentiated approach and long-term IP strength in the gene-editing space.
My Take: Beam’s tech is still early-stage, but the platform has blockbuster potential. While volatility is high, positive trial results or partnerships could catalyze the next leg higher. This is one to watch closely in the genomic medicine race.
Bloom Energy Corporation [BE] – Last Close: $24.30
Bloom Energy provides solid oxide fuel cell technology that delivers on-site, clean electricity to commercial and industrial clients. The company supports decarbonization initiatives across data centers, manufacturing, and critical infrastructure.
Shares are trading over 7% higher in the premarket session as investors react to renewed interest in alternative power systems amid global heatwaves and grid instability. Bloom’s strong presence in backup power and its expansion into hydrogen make it a standout in the energy transition theme.
My Take: Bloom is gaining traction as energy reliability becomes mission-critical. It’s not without risk, as competition and capex are concerns, but the long-term growth story tied to grid modernization is compelling.
AI Potential (Sponsored)
While headlines focus on the same overhyped AI names, a bigger opportunity is taking shape — and it’s flying under the radar.
A new report reveals 9 AI companies with real U.S. operations, accelerating revenue, and deep AI integration. These aren’t speculative plays — they’re positioned to benefit from a massive shift in how and where AI is being built.
This free guide includes:
A chip supplier poised to fuel U.S. AI manufacturing
A cloud provider set to expand under new policy changes
A data firm with potential government contracts on deck
The early window on these opportunities may be closing — now’s the time to see what’s coming next.
Everything Else
Private equity firms are circling Starbucks China, with new bids valuing the franchise at up to $10 billion as the company explores strategic options.
Super Micro is doubling down on Europe, announcing plans to expand its AI infrastructure presence in the region.
Japan and South Korea are racing to negotiate tariff relief ahead of the looming August deadline.
Investors seeking refuge from market volatility pushed gold ETFs to their highest inflows in five years in the first half of 2025.
Ad giant WPP tumbled 16% and led the FTSE 100 lower after issuing its second profit warning of the year.
A 36% rally in SoFi followed analyst upgrades driven by crypto momentum and favorable student loan policy changes.
WPP spooked investors again with another downgrade to its earnings outlook, raising red flags on ad spend.
CoreWeave has quadrupled since its IPO, but some analysts are growing cautious as the hype accelerates beyond fundamentals.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
